Clinical Trials

Inclusion Criteria:

• Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher.
• Participant has adequate intravenous infusion access per investigator's judgement
• Willing to comply with study procedures including skin punch biopsies procedures.
• Weight is greater than 40 kg and less than 130 kg.

Exclusion Criteria:

• Skin disorders other than CLE or SLE.
• Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids.
• Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.
• Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
• Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.
• Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments.
• History of disseminated herpes zoster/simplex or recurrent herpes zoster.
• Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline.
• Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB)
• Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/03/2024. Questions regarding updates should be directed to the study team contact.